Enliven Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Enliven Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Enliven Therapeutics Inc
Rating: 1.11075
Author: Trendlyne DVM scores

about

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product...

18.57 -0.63 (-3.28%)

38.16% Fall from 52W High

275.6K

XNAS Volume

XNAS 25 Sep, 2025 4:05 PM (EDT)

Not Eligible

Expensive Valuation

9.0 / 100

Technically Neutral

35.4 / 100

No estimates available

Enliven Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Enliven Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product...

38.16% Fall from 52W High

SWOT Analysis

Enliven Therapeutics Inc Live Price Chart